Core Viewpoint - The legal opinion letter confirms that the procedures for convening and holding the 2025 third extraordinary general meeting of Ningxia Zhongke Biotechnology Co., Ltd. comply with relevant laws and regulations, as well as the company's articles of association [1][2][5]. Group 1: Meeting Procedures - The company announced the notice for the third extraordinary general meeting on August 16, 2025, through major financial publications and the Shanghai Stock Exchange website, detailing the meeting's time, location, agenda, and registration methods for shareholders [2][3]. - The meeting utilized a combination of on-site and online voting, with specific time slots for voting through the Shanghai Stock Exchange's systems [3][4]. Group 2: Attendees and Qualifications - The meeting was convened by the company's board of directors, with the chairman, Mr. Fu Jie, presiding over the session [4]. - A total of 256 shareholders or their representatives attended the meeting, holding 220,151,990 shares, which accounted for 32.14% of the total voting shares [4][6]. Group 3: Agenda and Voting Results - The agenda included a proposal regarding the company's new related party relationships and the expected daily related transactions for 2025 [5]. - The voting results showed that 218,998,690 shares (99.4761%) approved the proposal, while 1,105,500 shares (0.5021%) opposed it, and 47,800 shares (0.0218%) abstained [5][6]. Group 4: Conclusion - The legal opinion concludes that all aspects of the meeting, including the convening, attendee qualifications, voting procedures, and results, are in compliance with applicable laws and the company's articles of association [6].
ST宁科: 关于宁夏中科生物科技股份有限公司2025年第三次临时股东会法律意见书